Latest News

Xceleron latest presentation – The successful application of carbon isotopes in preclinical and clinical pharmaceutical research

October 6, 2015

Presented at the 21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, International Isotope Society-Central European Division, Bad Soden, Germany

Download the presentation from here


Xceleron Webinar – Genentech and GSK discuss microtracer use

September 16, 2015

Successful Clinical [14C] Microtracer Investigations – Case Studies from GSK and Genentech

Thursday, 24th September 2015 at 11:00 am EDT – 12:00 pm EDT

Go here to pre-register for the webinar


Xceleron giving Plenary Lecture at 21st Annual IIS-CED Workshop, Bad Soden Germany, 2nd October

August 17, 2015

Stephen English – “The successful application of carbon isotopes in preclinical and clinical pharmaceutical research”

Friday, 2nd October 2015

International Isotope Society-Central European Division

21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds

Bad Soden, Germany



Xceleron latest presentation

June 11, 2015

Surveying the Boundaries of Accelerator Mass Spectrometry: The Widening Scope of an Evolving Technology

Read the presentation


New Xceleron presentation 9th June

June 1, 2015

Stephen English Surveying the boundaries of accelerator mass spectrometry: the widening scope of an evolving technology
12th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, Princeton NJ
June 9th
16:20 – 16:40
Session 6
McDonnell AO1


New webinar materials are now available to view

April 22, 2015

Go here to download speaker presentations, listen to and watch a recording of the presentations or read our comprehensive Q&A


How AMS detection works

April 1, 2015

Our concise two-pager was written by our AMS engineer Eric Guarin

Download How AMS Detection Works


Xceleron Webinar 26 March 2015

March 18, 2015

Successful clinical 14C microtracer investigations: What can contemporary AMS do for you?

Register here


Xceleron Retains Professor Graham Lappin as Subject-Matter Expert

January 26, 2015

Expertise enables new AMS applications, Xceleron grows analytical operations

(Germantown, MD, USA; January 26, 2015) –Xceleron, a leader in the use of microtracers and Accelerator Mass Spectrometry (AMS) in novel life sciences investigations, has announced that it is retaining the consulting services of Graham Lappin (Visiting Professor of Pharmacology at the University of Lincoln, UK). Professor Lappin will advise the company and its customers on the application of microtracers in drug target research, clinical development and new non-pharmaceutical applications.

Professor Lappin has a long history and deep connections with the company going back to its early days. He also played an important role during Xceleron’s growth from a research-oriented laboratory in the UK to present-day in the US where it develops robust fit-for-purpose analytical methodology associated with AMS.

“Our relationship with Graham is important at this time for Xceleron” said Dr Michael Butler, CEO of Xceleron. “We have established a reputation for delivering representative, accurate and precise analytical data using AMS detection. This has been achieved by hiring accomplished analytical chemists who can develop and validate robust analytical methods around AMS. We are now turning the company’s full-time resources to scaling-up that service. Graham will help us customize our approach to novel cost-efficient clinical investigations and to continue applying our analytical expertise in new areas of drug research and non-pharmaceutical product development”


Xceleron and Molecular Profiles Announce Biopharmaceutics Partnership

October 30, 2014

We are pleased to announce a new partnership between Xceleron and biopharmaceutics technology leader Molecular Profiles.

The alliance aims to simplify biopharmaceutics decisions using technology and efficient design of clinical investigations.  Molecular Profiles has developed a unique Molecular Profiles Roadmap to investigate, evaluate and recommend a formulation development pathway that is the best option based on science.  Xceleron has developed a scientifically superior approach to determining clinical drug disposition using LC + AMS.  Together we can satisfy a real market need for science and technology to efficiently help with clinical biopharmaceutics decisions.

We look forward to a very active relationship with Molecular Profiles along the lines of that established with JCL.



  • Latest News

    Pharmaron Acquires Majority Stake in SNBL CPC

    Read more »

  • What our clients are saying about us...

    "...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."

    See more client quotes »

  • Get Phase II Ready

    Find out how we can help you accelerate your drug-development program.

    Email us now »

© Xceleron 2018 All Rights Reserved.